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Abstract: Allergic mechanisms are likely involved in atherosclerosis and its clinical presentations,
such as coronary artery disease (CAD). It has been previously reported that CAD severity asso-
ciates with serum levels of immunoglobulin E (IgE), the molecule that, along with its high-affinity
receptor (FcεRI), plays a central role in allergic reactions. Considering multiple pathophysiological
similarities between atherosclerosis and acquired aortic (valve) stenosis (AS), we speculated that
allergic pathways could also contribute to the AS mechanisms and grading. To validate this hypoth-
esis, we first checked whether total serum IgE levels associate with echocardiographic markers of
AS severity. Having found a positive correlation between serum IgE and aortic valve area (AVA),
we further speculated that also total IgE-determining genetic polymorphisms in FCER1A, a locus
encoding an allergen-biding FcεRI subunit, are related to acquired AS severity. Indeed, the major
allele of rs2251746 polymorphism, known to associate with higher IgE levels, turned out to corre-
late with larger AVA, a marker of less severe AS. Our findings surprisingly suggest a protective
role of IgE pathways against AS progression. IgE-mediated protective mechanisms in AS require
further investigations.
Keywords: aortic valve area (AVA); aortic (valve) stenosis (AS; AVS); FcεRI α-subunit (FcεRIα)
gene (FCER1A); (genetic) polymorphism; high-affinity IgE receptor (FcεRI); immunoglobulin E (IgE)
1. Introduction
The immune system plays an essential role in the development and progression of
atherosclerosis and related diseases, including coronary artery disease (CAD), periph-
eral artery disease, and stroke. Moreover, there is a growing body of evidence for the
contribution of allergic mechanisms, such as those related to the immunoglobulin E (IgE)
network, to the pathogenesis of atherosclerosis [1–3]. The IgE network comprises proteins
associated with IgE activity, including its two principal receptors, the high- (FcεRI) and the
low-affinity IgE receptors [4,5].
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Previous studies have demonstrated that the severity of CAD associates with total
serum IgE levels [6–8]. In turn, atherosclerosis shares multiple pathophysiological features
and risk factors with aortic (valve) stenosis (AS) [9–11], the most common acquired heart
valve disease, and another chronic vascular inflammatory disorder [9,12]. Therefore,
we hypothesized that AS severity may also be related to the IgE network. To verify this
speculation, we sought to investigate the associations between AS severity and total serum
IgE concentrations as well as the polymorphisms in the gene encoding the α-subunit of
FcεRI (FCER1A) representing the two tagging bins constituting the primary total serum
IgE susceptibility loci [13–16].
2. Experimental Section
2.1. Study Subjects
A total of 115 consecutive patients with acquired AS, recruited between March 2015
and November 2017, represented the original study group, in which total serum IgE levels
were assessed (Table S1). The Jagiellonian University Ethical Committee approved the
study, and all the participants provided their written informed consent. AS was defined as
a mean transvalvular gradient greater than or equal to 40 mm Hg and/or aortic valve area
(AVA) less than 1 cm2 on the basis of transthoracic echocardiography, performed by an
experienced cardiologist using a Vivid 7 ultrasound equipment (GE Healthcare, Chalfont St
Giles, UK).
For the purposes of the genetic association study of AS severity, we enriched the
original group with an additional 305 acquired AS patients, recruited for our previous
studies between September 2009 and May 2012 [17,18], thus forming the expanded study
group of 420 subjects in total (Table S2).
All patients were originally referred to either the Department of Cardiology, John Paul
II Hospital, or the Department of Cardiovascular Surgery and Transplantation, Jagiel-
lonian University School of Medicine, both in Krakow, Poland, for further diagnostic
work-up, and all came from the Malopolska region in the south of Poland. The exclusion
criteria were acute infection; Valsalva sinus aneurysm or rheumatic AS; known cancer;
autoimmune or allergic disorders; endocarditis; previous cardiac surgery; liver failure with
an alanine aminotransferase above the upper limit of the reference range; and a history of
myocardial infarction (MI), stroke, venous thromboembolism, or bleeding.
2.2. Laboratory Tests
Total serum IgE was assayed using ELISA (Biokom, Janki k/Warszawy, Poland).
C-reactive protein (CRP) was determined by immunoturbidimetry (Roche Diagnostics,
Mannheim, Germany).
2.3. Genotyping
DNA was extracted from whole blood or a buffy coat using the NucleoSpin Blood
DNA Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s proto-
col. FCER1A rs2252226 and rs2251746 variants were genotyped for the purposes of the
present study using C_15886139_10 and C_1840470_20 TaqMan SNP Genotyping Assays
(Applied Biosystems, Thermo Fisher Scientific, Foster City, CA, USA), respectively. Geno-
typing methodology has been validated in a control group comprising healthy individuals,
as previously reported [19]. Both polymorphisms were successfully genotyped in AS
patients with a call rate of about 98% and their genotypes remaining in Hardy–Weinberg
equilibrium (HWE; Table S3).
2.4. Statistical Analysis
The distribution of the continuous variables was analyzed with Shapiro–Wilk test.
Those normally distributed are presented as mean ± standard deviation. Variables with
the distribution different from normal are, if not otherwise indicated, given as median
[interquartile range] and were analyzed with Mann–Whitney test or Kruskal–Wallis test
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(and then, if required, also with Jonckheere–Terpstra trend test). Adjustments for potential
categorical and continuous confounders were performed using analysis of covariance
(ANCOVA), with variables having distribution different from normal subjected to square-
root transformation before entering the model. Associations between two continuous
variables were calculated using Spearman’s coefficient of rank correlation. Adjustments for
potential categorical and continuous confounders were conducted using least squares
multiple regression, with variables having distribution different from normal subjected to
square-root transformation before entering the model. Conformity with HWE was tested
with the chi-squared goodness-of-fit test. Statistical calculations were performed using
MedCalc Version 18.10 (MedCalc Software, Ostend, Belgium) and Dell Statistica 13 (Dell,
Round Rock, TX, USA) programs.
3. Results
3.1. Correlations between Total Serum IgE Levels and Echocardiographic Parameters in Acquired
AS Patients
First, we sought to investigate whether the echocardiographic parameters correlate
with total serum IgE concentrations in AS patients. Although a mean or maximum gradient
and left ventricular ejection fraction were not associated with total serum IgE, we docu-
mented a positive correlation between IgE and aortic valve area (AVA; R = 0.27, P = 0.01;
Table 1, Figure 1). This correlation remained significant also after adjustment for age, sex,
BMI, and CRP levels (P <0.05).
Table 1. Correlations of total serum immunoglobulin E (IgE) levels (IU/mL) with echocardiographic parameters in patients
with acquired aortic stenosis (n = 115).
Echocardiographic Parameter Number of Data Pairs Spearman’s RankCorrelation Coefficient (R) P-Value
Mean aortic gradient, mm Hg 100 −0.11 0.28
Maximum aortic gradient, mm Hg 95 −0.06 0.55
Left ventricular ejection fraction, % 101 −0.03 0.75
Aortic valve area, cm2 82 0.27 0.01
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Figure 1. Correlation between aortic valve area and total serum immunoglobulin (IgE) levels in 
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Figure 2. Median aortic valve area in acquired aortic stenosis patients having different genotypes of 
the high-affinity immunoglobulin E receptor α-subunit locus (FCER1A) rs2251746 polymorphism. 
Boxes range from the 25th to the 75th percentile with a horizontal line at the median and vertical 
lines extending to the 10th and 90th percentiles. P-values calculated using Mann–Whitney test are 
given. P-values of less than 0.05 are marked with a star (“*”). 
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Finally, we investigated whether FCER1A polymorphisms associated with total IgE 
in AS subjects. The rs2251746 polymorphism tended to be associated with total serum IgE 
(P = 0.09), with the highest values in TT and the lowest in CC homozygotes (Table S4). 
Furthermore, contrasting carriers of the T allele or TT homozygotes with CC homozy-
gotes demonstrated lower IgE in the latter group (P = 0.03 in both; Table S4). In turn, 
although TT homozygotes of the rs2252226 polymorphism had the lowest and CC ho-
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Figure 1. Correlation between aortic valve area and total serum immunoglobulin (IgE) levels in
acquired aortic stenosis patients calculated using Spearman’s coefficient of rank correlation (R).
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3.2. Association between FCER1A Polymorphisms and AVA in Acquired AS Patients
In the second step, in a large group of 420 AS subjects, we analyzed the relationships
between FCER1A polymorphisms and AVA. The rs2252226 polymorphism was not as-
sociated with AVA (TT, n = 122, 0.73 [0.56–0.93]; TC, n = 177, 0.72 [0.60–0.95]; and CC,
n = 64, 0.79 [0.59–0.90]; P = 0.91). However, the rs2251746 polymorphism demonstrated a
significant association with AVA (TT, n = 198, 0.80 [0.60–0.95]; TC, n = 139, 0.71 [0.59–0.90];
and CC, n = 26, 0.65 [0.50–0.80]; P = 0.04, Ptrend = 0.02), which remained significant after
adjustment for age, sex, BMI, and CRP levels (P = 0.02). Moreover, contrasting minor or
major homozygotes with the reminder as well as opposite homozygotes with each other
also yielded significant results (P = 0.0498, P = 0.03, and P = 0.03, respectively; Figure 2).
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Figure 2. Median aortic valve area in acquired aortic stenosis patients having different genotypes of
the high-affinity immunoglobulin E receptor α-subunit locus (FCER1A) rs2251746 polymorphism.
Boxes range from the 25th to the 75th percentile with a horizontal line at the median and vertical
lines extending to the 10th and 90th percentiles. P-values calculated using Mann–Whitney test are
given. P-values of less than 0.05 are marked with a star (“*”).
3.3. The Effects of FCER1A Polymorphisms on Total Serum IgE in Acquired AS Patients
Finally, we investigated whether FCER1A polymorphisms associated with total IgE in
AS subjects. The rs2251746 polymorphism tended to be associated with total serum IgE
(P = 0.09), with the highest values in TT and the lowest in CC homozygotes (Table S4).
Furthermore, contrasting carriers of the T allele or TT homozygotes with CC homozygotes
demonstrated lower IgE in the latter group (P = 0.03 in both; Table S4). In turn, although TT
homozygotes of the rs2252226 polymorphism had the lowest and CC homozygotes the
highest total serum IgE values, the differences were not significant (Table S4). Only a
tendency towards an association was observed when TT homozygotes were contrasted
with the carriers of the C allele (P = 0.07; Table S4).
4. Discussion
To our knowledge, relationships between IgE network and acquired AS severity
have not been investigated thus far. However, on the basis of the mechanistic similarities
between AS and CAD [9,10], as well as previously reported correlations between the
severity of CAD and IgE levels [6–8], we speculated that similar relationships could also be
observed in AS.
Indeed, we found significant and robust associations between the elements of the IgE
network and AS severity, but their directions were opposite to what we had originally ex-
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pected. Specifically, larger AVA indicating less advanced AS [20] correlated with increased
serum IgE concentrations. Furthermore, the major allele of the rs2251746 polymorphism,
known to be strongly associated with elevated total serum IgE levels [13–16], was related
to the higher AVA. These are intriguing and unexpected findings requiring a comment.
An increase in FcεRI expression might lead to higher concentrations of IgE in serum,
for instance, through the stabilizing effect of mast cell or basophil receptor on IgE upon
binding [21,22]. This might mechanistically explain the association of the major allele of
the rs2251746 polymorphism [4], shown to increase FCER1A promoter activity and thus
FcεRI(α) expression [23,24], with higher total IgE in serum. Hence, our current results
might suggest that higher total serum IgE and/or cell surface FcεRI expression levels
protect against the development of more severe forms of AS. Mechanisms behind that
effect remain unclear, particularly because numbers of mast cells in pathologically altered
aortic valve tissue in AS correlate positively with disease severity, thus inversely with
AVA [25]. However, it has been reported that cardiac mast cells are activated directly
predominantly by noxious metabolic agents or neuropeptide substance P via MAS-related
G protein-coupled receptor-X2 (MRGPRX2) and not through the IgE–FcεRI-dependent
pathway [26–30]. Therefore, one might speculate that other FcεRI-expressing cell types
might contribute to the protective role of the IgE network in AS progression, such as mono-
cytes or macrophages. Monocytes play an essential role in each AS cardinal component,
including inflammation, fibrosis, and calcification [31]. These cell populations may remodel
tissue matrices, regulate fibrosis, and structural repair. Furthermore, active recruitment
of circulating monocytes into the valve is increased with age, promoting differentiation
into macrophages and degenerative valvular changes. In turn, although cross-linking of
IgE-FcεRI complexes on monocytes might increase secretion of pro inflammatory tumor
necrosis factor α (TNFα) and interleukin-6 (IL-6), it also significantly upregulates the pro-
duction of IL-10, limiting the further development of inflammation. Moreover, IgE binding
could critically impair these cells’ phagocytic function, a primary mechanism contributing
to the tissue injury repair and extracellular matrix remodeling [32,33]. It is worth mention-
ing that patients with more severe AS are characterized by increased circulating monocyte
numbers, which interestingly correlate with AVA [34]. Thus, monocyte-related inflam-
mation seems to be critical in a more severe stage of the disease. Our outcomes indicate
an auxiliary role of IgE network in this regulation, although extensive observational and
experimental studies are needed to verify the above hypothesis. The findings and the
speculations potentially providing them with some mechanistic explanations are presented
in Figure 3.
Another possible explanation of the observed relationship might be a linkage disequi-
librium between rs2251746 polymorphism and genetic variants in another gene localized
distantly from FCER1A and not directly related to the IgE network. For example, a strong
correlation was observed between a FCER1A polymorphism belonging to the same tagging
bin as rs2251746 and the expression of OR10J5, a gene located about 250 kb upstream [35].
One cannot exclude a similar relationship between rs2251746 and another gene on chro-
mosome 1, which is not directly related to the IgE network but has anti-inflammatory or
immune modulating properties, slowing the AS progression. In this scenario, the effect of
the rs2251746 polymorphism on serum IgE would be functionally meaningless, at least in
the context of the AS severity, although higher total serum IgE could be used as a biomarker
of the less severe AS. The contribution of other mechanisms, however, cannot be excluded.
Our study has several limitations. Most importantly, total serum IgE was not measured
in all analyzed subjects. The reason behind this was the design of the study, with the
original group (Table S1) being a screening group for detection of the association between
IgE network and acquired AS severity and the expanded group (Table S2) designated for
genetic association testing without IgE level analysis. Other limitations, such as a lack of a
replication group or functional studies, make our results preliminary, matching the type of
this report, i.e., communication.
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